McKesson said it raised and narrowed its Fiscal 2026 Adjusted Earnings per Diluted Share guidance range to $38.05–$38.55 from the previous range of $37.10–$37.90.

1. 01

   McKesson said it raised and narrowed its Fiscal 2026 Adjusted Earnings per Diluted Share guidance range to $38.05–$38.55 from the previous range of $37.10–$37.90.

2. 02

   The company said it increased its long-term Adjusted Earnings per Diluted Share growth target to 13%–16% from the prior range of 12%–14%. It said this target reflects the strength of McKesson's leading platforms in oncology, multispecialty, and biopharma solutions.

3. 03

   McKesson introduced long-term Adjusted Segment Operating Profit growth targets for its newly defined segments: North American Pharmaceutical 5%–8%, Oncology & Multispecialty 13%–16%, and Prescription Technology Solutions 10%–13%.

4. 04

   The company said it will introduce the new organizational structure announced on September 18, 2025 at its Investor Day and provide an update on portfolio developments, including the Medical-Surgical separation.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.